INTRODUCTION {#s1}
============

*SOX9* \[sex-determining region Y (SRY)-box 9 protein\] is a transcription factor that regulates development under normal circumstances. *SOX9* and other members of the SOX family have conserved structural features including a high mobility group (HMG) box DNA-binding domain, as well as a transactivation domain. The range of functions that Sox proteins serve is broad, including maintaining stem cell features, restricting lineage, and directing terminal differentiation. Germline *SOX9* heterozygous inactivating missense and nonsense mutations result in campomelic dysplasia, a syndrome resulting in skeletal malformations, central nervous system dysfunction, as well as abnormalities in other organs \[[@R1]--[@R2]\].

In the context of cancer, *SOX9* has been classified as both tumor suppressor and oncogene depending on the study and type of cancer being investigated. Evidence suggesting its role as a tumor suppressor is derived from several tumor types. SOX9 has decreased expression in cervical carcinoma compared to normal cervical tissue, and *in vitro* inhibited cell growth and tumor formation when overexpressed \[[@R3]\]. In prostate cancer, *SOX9* overexpression has been show to decrease cell proliferation and increase apoptotic activity.\[[@R4]\]. By contrast, both decreased *SOX9* activity and oncogenic features of SOX9 have been implicated in colorectal carcinoma (CRC) \[[@R5]--[@R7]\].

Recently, exome sequencing has identified *SOX9* as a recurrently mutated gene in colorectal carcinoma.\[[@R8]\]. The spectrum of mutations, effect on protein expression, molecular correlates, and clinical features has not been characterized to date. Here, we characterize the spectrum of *SOX9* mutations, their molecular and clinical correlates, and their effect on SOX9 protein expression in comparison to *SOX9* wild type (WT) carcinoma and normal epithelium within the context of CRC.

RESULTS {#s2}
=======

Characteristics of *SOX9* mutations in CRC {#s2_1}
------------------------------------------

Mutations discovered were either frameshift or nonsense mutations in 31 of 38 (81.6%) of *SOX9* mutant CRC. Each of the 38 *SOX9* mutations was unique, without recurrent mutations (Figure [1A](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}). There were 23 frameshift mutations, 12 nonsense mutations, 8 missense mutations, and 1 in frame deletion. The most frequently mutated exon was the last one (exon 3), which harbored predominantly nonsense and frameshift mutations (92%), while frameshift and truncating mutations only made up 44% of exon 1 mutation and 78% of exon 2 mutations (*p* = 0.02 for truncating mutations in exon 3 *versus* exons 1-2). There were 9 mutations in exon 1 (4 missense, 1 in frame deletion, 1 nonsense, and 3 frameshift), 9 mutations in exon 2 (2 missense mutations, 2 nonsense mutations, and 5 frameshift mutations) and 23 mutations in exon 3 (2 missense mutations, 9 nonsense mutations, and 15 frameshift mutations). TCGA data was similar to institutional data in that the majority of *SOX9* mutations detected were frameshift or nonsense. Further, the *SOX9* mutant CRC in TCGA data displayed transcriptional upregulation of SOX9 (Figure [1B](#F1){ref-type="fig"}).

![*SOX9* mutation distribution and transcription levels\
**A.** *SOX9*, which only has 3 exons (delineated by black double forward slashes), has a conserved DNA dimerization domain (Dim), a homeobox group binding domain (HMG box) with two nuclear localization signals (black rectangles) that bind DNA, and transactivation domains (K2 and Transactivation Domain) as well as a PQA domain. *SOX9* mutations occurred as mostly frameshift and nonsense mutations (red circles) while scattered missense mutations (green circles) and an in frame deletion (black circle) were also detected. The majority of mutations preserved the dimerization and HMG box domains. **B.** TCGA data shows that, similarly to our institutional study cases, most *SOX9* mutations are frameshift or nonsense. The mutations have increased RNA transcription levels on RNA sequencing.](oncotarget-07-50875-g001){#F1}

###### *SOX9* mutations, zygosity, and expression

  Exon    Amino-acid change                                                   Nucleotide change                 Predicted AA length   TP (%)   AF (%)   H score (IHC)   Oncoscan result          Site Tested
  ------- ------------------------------------------------------------------- --------------------------------- --------------------- -------- -------- --------------- ------------------------ -------------------
  1       E57Qfs\*50                                                          168_179delinsAG                   107                   22       45       300                                      liver
  1       E134\*                                                              400G\>T                           134                   10       11       0                                        primary
  2       E159Gfs\*25                                                         474_475dupGG                      184                   20       21       60                                       peritoneum
  2       E190\*                                                              568G\>T                           190                   46       33       140                                      primary
  2       Q208\*                                                              622C\>T                           208                   25       50       0                                        primary
  2       S215Pfs\*4                                                          643delT                           219                   11       7        300                                      primary
  2       E191Rfs\*28                                                         571delG                           219                   18       24       300                                      peritoneum
  2       Q164\*, E226\*                                                      490C\>T, 676G\>T                  226                   50       10       130                                      primary
  2       D168Efs\*84                                                         503dupA                           252                   48       39       70                                       liver
  1       W143Lfs\*109                                                        427dupT                           252                   70       67       190             Gain, LOH                recurrence
  3       V245Gfs\*7                                                          733dupG                           252                   50       25       300                                      liver
  3       Q246Cfs\*8                                                          734_735dupTG                      254                   53       36       60                                       primary
  3       L259\*                                                              776T\>A                           259                   60       61       0                                        liver
  3       P267Sfs\*9                                                          798_807delCCCTATCGAC              276                   30       14       160                                      primary
  3       G263Afs\*16                                                         788delG                           279                   25       13       1                                        primary
  3       D274Wfs\*6                                                          818_819dupTG                      280                   40       29       300                                      primary
  3       E277D, S279Afs\*104                                                 831G\>C, 834delG                  293                   20       40                                                primary
  3       Q312\*                                                              934C\>T                           312                   30       82       300             Hypotriploid, LOH        ovary
  3       W335\*                                                              1004G\>A                          335                   30       76       300             Gain, no LOH             peritoneum
  3       Q339\*                                                              1015C\>T                          339                   10       25       300                                      liver
  3       D290Mfs\*93                                                         868delG                           383                   50       44       300             Hypotetraploid, no LOH   primary
  3       P374Rfs\*9                                                          1212C\>A                          383                   20       53       300                                      primary, duodenum
  1,2,3   S23FS, T196A, R394\*                                                66delC, 586A\>G, 1180C\>T         394                   30       15                                                primary
  3       H396L, E400\* in cis                                                1187A\>T, 1198G\>T                400                   50       55       300             Gain, LOH                primary
  3       Q393Sfs\*10                                                         1177delC                          403                   50       25       300                                      primary
  3       H396Rfs\*8                                                          1185_1186dupGC                    404                   50       33       300                                      primary
  3       Q410\*                                                              1228C\>T                          410                   70       85       300             CN-LOH                   primary
  3       Q412\*                                                              1234C\>T                          412                   50       73       225             CN-LOH                   primary
  3       H406Sfs\*58                                                         1215_1234del                      464                   60       23       300                                      primary
  1       A118_A124del                                                        353_373delCGGCGCGCAGGAAGCTCGCGG   502                   54       21       300                                      primary
  2       A187V                                                               560C\>T                           509                   60       25       5                                        primary
  1       M113T                                                               338T\>C                           509                   90       28       90                                       primary
  1       M113V, R162H                                                        337A\>G, 485 G\>A                 509                   50       27       170                                      primary
  1       S39C                                                                116C\>G                           509                   90       45                                                primary
  3       V486A                                                               1457T\>C                          509                   25       20       250                                      recurrence
  3       A419T                                                               1255G\>A                          509                   10       11       250                                      primary
  3       R508_P509insGGL PRRAKMAEMILK ITEEREDQPEFPL DICVFLFFYFVLF FLLLLL\*   1525_1530+5delCCTTGAGGAGG         557                   10       18       0                                        primary
  3       M469Ifs\*109                                                        1406dupT                          578                   50       54       3                                        liver

Correlation of *SOX9* mutation frequency with known CRC genes {#s2_2}
-------------------------------------------------------------

In comparison to *SOX9* wild type CRC, *SOX9* mutant CRC was strongly associated with the presence of *KRAS* mutation (*p* = 0.0001) and the absence of *TP53* mutation (*p* = 0.0004). *SOX9* mutant CRC also had higher rates of *PIK3CA* mutation (*p* = 0.0451), a trend toward *APC* mutation (*p* = 0.0527), and MMR deficiency (*p* = 0.0472). Interestingly, the majority of *SOX9* mutations in the MMR-D CRC were missense or nonsense and did not occur in mononucleotide tracts, while only 2 of the 10 SOX9 mutations in these 6 MMR-D, *SOX9* mutant CRC were frameshifts (both in mononucleotide tracts). None of the 38 SOX9 mutant CRC harbored *BRAF* or *NRAS* mutations, while 34 (10.8%) and 10 (3.2%) of *SOX9* WT CRC harbored *BRAF* and *NRAS* hotspot mutations, respectively (Table [2](#T2){ref-type="table"}).

###### Clinicopathologic and molecular characteristics of *SOX9* mutant *versus SOX9* WT CRC

                                       *SOX9* mutant (*n* = 38)   *SOX9* WT (*n* = 315)   *P* value
  ------------------------------------ -------------------------- ----------------------- --------------
  **Age (mean; median)**               60; 62                     55; 59                  
  **Sex (M:F)**                        22:16                      184:131                 
  **Location: cecum to transverse**    18                         107                     
  **Location: descending to rectum**   20                         208                     
  **Histology: mucinous, poor**        18%, 0                     4%, 10%                 
  **MMR-D**                            26%                        6%                      *P* = 0.0472
  ***KRAS* mutant**                    66% (25 of 38)             33% (123 of 315)        *P* = 0.0001
  ***NRAS* mutant**                    0                          11%                     
  ***BRAF* mutant**                    0                          3%                      
  ***APC* mutant**                     87%                        72%                     
  ***TP53* mutant**                    42% (16 of 38)             72% (227 of 315)        *P* = 0.0004
  ***PIK3CA* mutant**                  32%                        17%                     *P* = 0.0451

Correlation of *SOX9* mutation Type to immunohistochemical expression {#s2_3}
---------------------------------------------------------------------

All 22 *SOX9* WT CRC analyzed showed strong positive expression (mean H-score 296±19.2). (Figure [2A, 2C](#F2){ref-type="fig"}) while normal epithelium shows weak expression limited to deep crypts (Figure [2A, 2B](#F2){ref-type="fig"}). Overall, *SOX9* mutant CRC showed a wide range of H scores with a mean H-score (188.7±123.3, *p* value \< 0.001). However, closer review indicated that H scores in *SOX9* mutant CRC were highly related to both the type of variant and its site within the coding region of the *SOX9* gene. Truncating or missense exon 3 mutant CRC had higher H scores in comparison to other mutations (exon 1 or 2 mutant or exon 3 frameshift mutants resulting in loss of stop codon and predicted protein elongation) (*p* = 0.02): *SOX9* exon 1 or 2 mutant mean H score = 147, *SOX9* frameshifts resulting in loss of stop codon and predicted protein elongation had mutant mean H score = 2 (Figure [2A, 2D](#F2){ref-type="fig"}), exon 3 mutant CRC (excluding stop loss mutants) mean H score = 239 (Figure [2A, 2E](#F2){ref-type="fig"}).

![Mean SOX9 Expression (H Score) According to Mutation Status\
**A.** In comparison to normal epithelium (mean H score 40±7.9), which only shows SOX9 expression in deep crypt epithelium, the majority of both *SOX9* WT (mean H score = 296±19.2) and mutant CRC overexpressed SOX9. Among *SOX9* mutant CRC, truncating and missense exon 3 mutants had a higher mean H score (239±80.3) in comparison to other mutants including exon 1, exon 2, and exon 3 elongating mutants resulting in loss of stop codon (mean H score = 129±155.3), *p* = 0.02. **B.** Normal colorectal epithelium has nuclear SOX9 expression restricted to deep crypts. **C.** Strong, nuclear SOX9 expression is seen in *SOX9* wild type CRC. **D.** A *SOX9* p. Q312X mutant with loss of the normal allele displayed strong SOX9 nuclear expression. **E.** A *SOX9* frameshift mutants resulting in loss of the stop codon with paucity of nuclear SOX9 expression.](oncotarget-07-50875-g002){#F2}

Overexpression of truncating *SOX9* mutations in the absence of a wild type allele {#s2_4}
----------------------------------------------------------------------------------

Zygosity analysis was performed on 7 SOX9 expressing (IHC) CRC with *SOX9* frameshift or nonsense mutations and high *SOX9* mutant allele frequencies in comparison to estimated tumor percent. Five of these 7 cases showed LOH at chromosome 17q24.3 where *SOX9* is located. Of these 5 cases, 2 cases displayed copy neutral (CN) LOH while 3 harbored gains of the mutant allele (Table [1](#T1){ref-type="table"}) in addition to LOH (Figure [3](#F3){ref-type="fig"}). The remaining two cases tested showed gain of the mutant allele yet retained the WT allele.

![Copy number and heterozygosity of *SOX9* mutants\
**A.** Oncoscan analysis of the *SOX9* p. Q312X mutant displayed in Figure [2D](#F2){ref-type="fig"} shows gain of *SOX9* (arrow shows increase in log2 copy number over chromosome 17 including *SOX9*) and **B.** loss of normal allele (arrows show splitting of beta allele frequency).](oncotarget-07-50875-g003){#F3}

Frequency of *SOX9* mutations in CRC and relationship to clinical features {#s2_5}
--------------------------------------------------------------------------

From January 1^st^ 2014 to December 31^st^, 2015; 353 CRC patients underwent MSK-IMPACT testing. Of these, 38 (10.7%) harbored *SOX9* mutations. *SOX9* mutant CRC did not differ from *SOX9* WT CRC in male to female ratio, patient age distribution, WHO morphologic subtype distribution, or primary tumor location (proximal *versus* distal) (Table [2](#T2){ref-type="table"}). Patients with metastatic *SOX9* mutant CRC (*n* = 317) had longer overall survival in comparison to those with *SOX9* WT on univariate analysis (log rank *p* value = 0.049) (Figure [4A](#F4){ref-type="fig"}). To adjust for microsatellite status because MSI-H was more frequent in SOX9 mutant CRC, we compared overall survival in MSS CRC with *versus* without *SOX9* mutation. In this microsatellite stable analysis, 11 metastatic *SOX9* WT and 2 metastatic *SOX9* mutant CRC were MSI-H and excluded. Metastatic *SOX9* mutant CRC tended to have a longer overall survival of borderline statistical significance (log rank *p* value = 0.058) (Figure [4B](#F4){ref-type="fig"}).

![Survival curves of metastatic *SOX9* mutant and wild type CRC\
**A.** Overall survival from date of metastasis of *SOX9* mutant (green) and *SOX9* WT (red) are shown for the 317 CRC patients with metastatic disease (285 WT and 32 mutants) are shown. *SOX9* mutation was associated with better survival (log rank *p* value = 0.049) on univariate analysis. **B.** Adjusting for microsatellite instability, the overall survival of microsatellite stable (MSS) CRC are shown. This analysis excluded 2 microsatellite instability-high (MSI-H) *SOX9* mutant CRC and 30 MSI-H *SOX9* wild type CRC. MSS *SOX9* mutant CRC tended to have longer overall survival than *SOX9* wild type CRC from date of metastasis with borderline significance log rank *p* value of *p* = 0.058.](oncotarget-07-50875-g004){#F4}

Five patients with *SOX9* mutant, *RAS*/*RAF* WT CRC received anti-EGFR therapy (cetuximab or panitumumab) in combination with other treatment modalities (FOLFIRI, irinotecan). Of these, 3 (60%) showed progression of disease, 1 patient (unknown whether irinotecan naïve or not) received cetuximab and irinotecan and showed decreased tumor volume of hepatic metastasis, and 1 patient received adjuvant panitumumab with folfiri, floxuridine and a hepatic pump after metastatectomy and has not recurred.

DISCUSSION {#s3}
==========

In this study, we demonstrate several findings including the recurrent nature of truncating SOX9 mutations in CRC, the overexpression of SOX9 in the majority of both *SOX9* mutant (including those with *SOX9* LOH) and WT CRC, and the strong association of *SOX9* mutation with mutant *KRAS* and WT *TP53*.

The distribution and nature of *SOX9* mutations in CRC is similar to that seen in classic tumor suppressors, namely mostly truncating mutations across the length of the gene without hotspots. However, the fact that we found gain of the mutant *SOX9* allele as well as overexpression of the mutant allele in the absence of the WT allele argues that truncated *SOX9* may serve as an oncogene in CRC, or as a gain of function tumor suppressor gene as well described in the case of *TP53*. However, data across the Cancer Genome Atlas (TCGA) show that *SOX9* is altered in a pattern typically seen in oncogenes: it is mutated and amplified in multiple cancer types, and rarely is the whole gene deleted \[[@R11]\]. The higher expression of SOX9 for exon 3 truncating mutations is potentially due to the fact that exon 3 is the last exon in *SOX9*, and truncating mutations within the last exon do not activate nonsense-mediated decay.\[[@R13]\]. This, however, may not be true for *SOX9* mutations that extend the protein *via* distal frameshift mutations, removing the WT stop codon and activating nonstop mediated decay \[[@R14]\] both of our cases with distal *SOX9* exon 3 frameshift mutations with stop loss mutations had very low H scores for expression (0 and 3 out of 300).

Interestingly, studies have shown overexpression of an isoform of the SOX9 protein in CRC that is truncated due to retention of intron 2 (termed 'miniSOX9'), missing the transactivation domain yet still conserving the N terminal dimerization and DNA binding domains \[[@R15]\].

MiniSOX9 upregulates Wnt/β-catenin-dependent transcriptional activity and is associated with nuclear β catenin accumulation \[[@R16]--[@R18]\]. While one proposed explanation for this has been splice site mutations affecting intron 2, many CRC with miniSOX9 expression lack a mutational basis for the truncated and overexpressed SOX9 product. As the majority of *SOX9* mutations in CRC are truncating and result in deletion of the C-terminal protein including the transactivation domain, the protein product is predicted to be functionally similar to the MiniSOX9 isoform of SOX9.

The fact that truncated *SOX9* is highly associated with mutant *KRAS* and WT *TP53* has not been previously demonstrated. Wild type *SOX9* has been shown to cooperate with *RAS* mutants in several *in vivo* experiments \[[@R6]\] These experiments showed higher mRNA transcription levels of SOX9 when an *HRAS* codon 12 mutation was knocked in. These experiments also showed 5 times more tumor foci in a CRC cell line with *HRAS* codon 12 mutation when SOX9 was overexpressed in comparison to when SOX9 was not overexpressed \[[@R6]\] In regards to *TP53* status and correlation with *SOX9* mutation status, it has been found that overexpression of SOX9 results in lower levels of TP53 \[[@R6]\]. This indirect relationship may be due to SOX9 overexpression having decreased p14 levels, and p14 stabilizes TP53. Therefore, even though truncating *SOX9* mutations that result in SOX9 overexpression are associated with WT *TP53*, they may indirectly downregulate TP53 activity.

Finally, the correlation of *SOX9* mutation with longer survival has not been previously investigated. While we find that *SOX9* mutation is associated with increased survival in patients with metastatic CRC on univariate analysis (*p* = 0.049), we also know that *SOX9* mutation is associated with MMR deficiency in a non-random way as the majority of *SOX9* truncating mutations in MMR deficient CRC were not in mono- or di- nucleotide repeat areas. MMR deficiency has been shown to have a positive impact on prognosis \[[@R19]\]. Even after adjustment for microsatellite status, *SOX9* mutant MSS CRC tended to have longer overall survival than *SOX9* WT MSS CRC with borderline statistical significance (*p* = 0.058), suggesting that the *SOX9* mutation may positively affect prognosis independent of MSI status. A significant limitation within the survival data is that each patient\'s treatment cannot be compared or normalized for as there is a significant amount of variation.

In summary, we have provided evidence that truncating mutations in *SOX9* (particularly exon 3 truncating mutations) are recurrent in CRC and result in a truncated, overexpressed (in comparison to normal epithelium) protein that is likely oncogenic. These mutations are enriched in *KRAS* mutant, *TP53* WT cases; and are associated with better overall survival.

MATERIALS AND METHODS {#s4}
=====================

Molecular testing {#s4_1}
-----------------

After approval by the local institutional review board, data from all patients with CRC being treated at Memorial Sloan Kettering Cancer Center between January 1, 2014 and December 31, 2015 who had molecular testing with Memorial Sloan Kettering- Integrated Molecular Profiling of Actionable Targets (MSK-IMPACT) was analyzed. MSK-IMPACT molecular testing is performed on MSKCC patients with CRC harboring distant metastases for *KRAS*, *NRAS*, and *BRAF* status analysis. This panel uses patient\'s matched normal and tumor DNA to interrogate somatic mutations, structural variants, and copy number alterations in all coding regions and select introns of 410 cancer-related genes as previously described in full detail (see reference) \[[@R9]\]. Mutations in the following genes were recorded: *KRAS* (c. G12, G13, Q61, A59, K117, A146), *NRAS* (c. G12, G13, A59, Q61, K117, A146), BRAF (c. V600E, fusions), *APC* (all coding mutations), *TP53* (all coding mutations), *PIK3CA* (all coding mutations) and *SOX9* (all coding mutations). Microsatellite instability (MSI) was assessed with MSIsensor \[[@R10]\] on next generation sequencing (NGS) data for cases that did not have mismatch repair (MMR) immunohistochemical (IHC) analysis for MLH1, PMS2, MSH2, and MSH6 expression retention (MMR-P) or loss (MMR-D). Tumor purity was estimated by a combination of histologic assessment and mutation allele frequencies. Possible candidates with *SOX9* loss of heterozygosity (LOH) included cases with mutant *SOX9* allele frequencies that were higher than half the estimated tumor purity. Cases with suspected *SOX9* LOH were studied for allele-specific copy number by Affymetrix Oncoscan arrays, provided they had sufficient remaining DNA.

Additionally, RNA transcription level data on *SOX9* mutant and WT CRC from The Cancer Genome Atlas (TCGA) was reviewed *via* cbioportal \[[@R11]\].

Immunohistochemistry (IHC) {#s4_2}
--------------------------

A cohort of 22 *SOX9* WT and all available (*n* = 35) *SOX9* mutant CRC underwent SOX9 IHC staining on whole sections of formalin fixed, paraffin embedded tissue. Immunohistochemical analysis for SOX9 expression was performed with the rabbit monoclonal SOX9 antibody, EPR14335-78 (Abcam, Cambridge, MA). Both the intensity of staining (0-3) and the percent of tumor cells staining (0-100%) were recorded for nuclear SOX9 IHC expression and used to generate a Histo (H) score that ranged from 0-300 \[[@R12]\]. Immunohistochemical overexpression of SOX9 was interpreted relative to normal colorectal epithelium.

Clinical assessment {#s4_3}
-------------------

Electronic medical records were used to obtain data points including sex, age, tumor histology according to World Health Organization classification, primary site classified as either 'proximal' extending from cecum to distal transverse colon or 'distal' extending from splenic flexure to rectum, response to anti-EGFR therapy, time from metastasis to death were recorded.

Statistical analysis {#s4_4}
--------------------

Statistical analysis was performed using Fisher\'s exact tests with two-tailed p values for categorical data, and unpaired Student\'s t tests for comparison of continuous data (IHC H scores). P values less than 0.05 are mentioned. P values less than 0.01 were considered statistically significant to approximately account for multiple hypothesis testing. Kaplan-Meier curves were drawn and a log-rank p-value was computed to compare survival from time of metastasis based on *SOX9* status for 317 patients who developed metastatic disease, including 285 *SOX9* WT and 32 *SOX9* mutant patients.
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